HEALTH TECHNOLOGY

L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

L2Mtech | February 17, 2021

  • CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications.
  • CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications
  • CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications
  • CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications
  • CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications
  • CE Mark Approval for FlexiTrack 035™, Peripheral Balloon Catheter for Endovascular Applications

Bonn, Germany – L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products:

  1. LimusTrack™ : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the treatment of coronary artery disease, de novo lesions, restenosis lesions.
  2. LomiFlow™ : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease, small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases.
  3. PearlFlow™ : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease, PTA, dilatation of stenotic segments or lesions in peripheral arteries.
  4. PearlFlow NS™ : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial disease, de novo lesions, lesions in femoropopliteal arteries.
  5. FlexiTrack 018™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in femoral, popliteal, tibial arteries.
  6. FlexiTrack 035™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in the SFA, femoral arteries.

L2Mtech GmbH Founder and CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to the efficacy and safety of our innovative technology products for Cardiovascular and Endovascular applications.“

We now prepare to commercially launch the products in all markets where the CE Mark is recognized. With introduction of our innovative technology products in markets, we will be able to expand treatment options for the benefit of many millions of patients with coronary and peripheral artery disease around the world.

About L2Mtech
Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture and commercialization of medical devices that are used by healthcare establishments globally. L2MTech will provide interventional physicians with innovative vascular devices including Drug Eluting Balloon manufactured in Europe.Our Core mission is to build a product portfolio focused on minimally invasive treatment for patients with cardiovascular,endovascular and vascular artery disease. For further information, please visit : L2MTech.de

Media Contact:
L2Mtech GmbH
admin@L2Mtech.de
+49 228 94730761

Spotlight

Infographics are images that are used to describe complex data in a visually appealing and easy to understand way. The Communicable Disease Control and Prevention Bureau has developed a series of infographics to provide a different perspective of disease statistics in Montana. New infographics are added frequently and sorted by category. Learn more about communicable diseases by selecting a tab below. Each thumbnail image is linked to a pdf version of the infographic.

Spotlight

Infographics are images that are used to describe complex data in a visually appealing and easy to understand way. The Communicable Disease Control and Prevention Bureau has developed a series of infographics to provide a different perspective of disease statistics in Montana. New infographics are added frequently and sorted by category. Learn more about communicable diseases by selecting a tab below. Each thumbnail image is linked to a pdf version of the infographic.

Related News

HEALTH TECHNOLOGY

Medidata Announces Expansion with the Addition of 10 Tech Innovators to its Sensor Cloud Network

Medidata and Dassault Systèmes | June 30, 2022

Ten incredibly inventive companies have joined Medidata's ground-breaking Sensor Cloud Network, according to the Dassault Systèmes firm. The first cross-sector partnership is now made up of AliveCor, Aural Analytics, Biobeat, Blue Spark Technologies, Glooko, Indie Health, University of Arizona, Carnegie Mellon University, University of Rochester, and University of Vermont. Its goals include resolving issues with sensor integration, standardizing sensor data, and creating new digital biomarkers and algorithms. These will contribute to the development of new digital endpoints that might lead to the development of more potent therapies and improved patient care. The Sensor Cloud Network offers data scientists the chance to develop, test, and deliver physiological algorithms with clinical relevance at scale. The network consists of contract research organizations (CROs), device manufacturers, drug and vaccine developers, analytics firms, and academic institutions. Detailed motion characteristics including gait, cardiovascular measures, metabolic insights, and voice analytics of the highest caliber are a few examples. “As the use of sensors in clinical trials is predicted to reach 50% by 20251, we are focused on making Medidata Sensor Cloud the industry standard for collecting and analyzing medical-grade sensor data. “We are excited to work with a diverse group of partners to help shape the future of patient data collection and analysis, and make Sensor Cloud the platform of choice for developing new digital biomarkers across a wide variety of therapeutic areas.” Ben Schlatka, Vice President, Digital Biomarker Solutions, Medidata

Read More

HEALTH TECHNOLOGY

Greenway Health Announces New Greenway Medical Coding Services to Help Providers Ensure Accuracy, Reduce Denials and Diminish Administrative Burden

Greenway Health | July 20, 2022

Greenway Health, a leading health information technology services provider, launched Greenway Medical Coding services, its newest healthcare solution for ambulatory practices. Greenway Medical Coding enables practices to capture cost efficiencies, improve practice earning potential, and collect insurance payments efficiently with the knowledge and precision of a personalized coding team. Medical coding is the transformation of medical diagnoses, procedures, and services into a universal alphanumeric code. These comprehensive codes are used to submit and process charges in the healthcare billing system. Greenway Medical Coding will provide coding services by a dedicated team of professional coders certified by the American Academy of Professional Coders (AAPC) and/or American Health Information Management Association. "With 69 percent of healthcare leaders reporting an increase in denials in 2021, Greenway Medical Coding relieves staffing issues and decreases the number of denials so practices can focus on what they do best – taking care of patients. Our new medical coding solution is a way for us to help clients reduce denials, minimize risks, and improve overall patient satisfaction David Cohen, Chief Product and Technology Officer Greenway clients will benefit from the multi-specialty expertise of certified medical coders experiencing cleaner claims with faster insurance payments, access to auditing services, and efficient medical coding submissions. "Greenway is dedicated to providing the right tools for our clients to be successful and improve patient care," said Pratap Sarker, CEO of Greenway Health. "After listening to the struggles providers have had with maintaining coding staff, we knew we needed to provide a solution to relieve their administrative burden and allow for our providers to focus on patients." Greenway is an end-to-end EHR, practice management, and medical billing solutions provider with a full suite of adaptable technology options including revenue cycle management, telehealth, care coordination services, patient engagement, and much more. About Greenway Health Greenway Health provides electronic health records (EHR), practice management, and revenue cycle management solutions that help practices in multiple specialties grow profitably, remain compliant, work more efficiently, and improve patient outcomes. Its team of clinical, financial, and technology experts serve as trusted advisors, committed to enabling successful providers, empowering patients, and building healthier communities. Greenway works with more than 55,000 providers across multiple specialties, translating into millions of lives touched daily by its solutions.

Read More

HEALTH TECHNOLOGY

Carilion Clinic and TytoCare Come Together for the Expansion of Telehealth Offerings

Tyto Care | June 09, 2022

The healthcare industry’s first AI-powered modular device and examination offering, TytoCare has announced a partnership with Carilion Clinic, a premier not-for-profit organization focused on healthcare. Following the partnership, TytoCare will be integrated into Carilion’s virtual care solutions and will enhance the platform’s capabilities to provide virtual diagnosis and treatment and in-depth physical examinations in a virtual visit. "We're thrilled to partner with TytoCare, an innovative telehealth solution that provides our physicians with the clinical data crucial to diagnosing and treating patients remotely. We're excited to bring these telehealth capabilities to rural communities that have historically been unable to use this new standard of healthcare. TytoCare's technology is intuitive and easy-to-use for patients and providers and supplies our patients with the convenient, quality care they deserve." Stephen A. Morgan, M.D., Carilion Senior Vice President and Chief Medical Information Officer Rural communities make up over two thirds of those suffering from a shortage of primary care medical professionals in the U.S. and Carilion is providing care for over 1 million people in Virginia, most of them in rural communities. In addition, TytoCare’s hand-held examination kit is cleared by the FDA and enables users to conduct an in-depth physical examination of the skin, heart, throat, ears, abdomen, and lungs. "We're excited to work with Carilion to enhance the quality and scope of telehealth visits for both patients and their physicians through our market-leading solution. As health systems reimagine what primary care looks like in 2022, they quickly understand that more virtual-first options benefit the entire health ecosystem and can be used to increase access to first-rate healthcare regardless of geographic region. TytoCare's remote physical examinations ensure that virtual-first programs deliver thorough, quality care to patients, no matter where they live." Dedi Gilad, CEO and Co-Founder of TytoCare

Read More